The Food and Drug Administration yesterday authorized for emergency use a new drug to treat hospitalized patients receiving systemic corticosteroids who require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation. Actemra (tocilizumab) reduced the risk of death, ventilator use and time in the hospital for patients who received the drug in clinical trials. 

“Although vaccines have been successful in decreasing the number of patients with COVID-19 who require hospitalization, providing additional therapies for those who do become hospitalized is an important step in combating this pandemic,” said Patrizia Cavazzoni, M.D., director of FDA’s Center for Drug Evaluation and Research.

In other news, FDA is accepting comments through Aug. 24 on draft guidance encouraging clinical trials for cancer therapies to expand eligibility to patients with incurable cancers who have not previously received existing treatment options for their cancer. 
 

Related News Articles

Headline
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee today by a unanimous vote recommended that the FDA issue an…
Headline
The AHA has received a $1 million grant from the Centers for Disease Control and Prevention to continue for one year its efforts to encourage COVID-19…
Headline
The Food and Drug Administration yesterday released an updated enforcement policy related to face masks, barrier face coverings, face shields,…
Headline
The Centers for Disease Control and Prevention Friday updated its guidance for health care personnel on preventing and controlling infections during the COVID-…
Headline
According to new Centers for Disease Control and Prevention research, hospitalization for COVID-19 for children and adolescents increased four-fold in August…
Headline
The Centers for Disease Control and Prevention yesterday alerted health care providers and the public to reports of severe illness associated with using…